![]() ![]() You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Some better-ranked stocks from the biotech sector include Repligen Corporation RGEN and Vanda Pharmaceuticals VNDA, each carrying a Zacks Rank #2 (Buy). Blueprint Medicines Corporation Priceīlueprint Medicines Corporation price | Blueprint Medicines Corporation Quote Zacks Rank & Stocks to ConsiderĬurrently, Blueprint Medicines has a Zacks Rank #3 (Hold). The company anticipates to evaluate both candidates as a single-agent as well as a combination in the second half of 2021 to treat naïve EGFR-driven NSCLC. The company plans to start a phase I study of BLU-701, a double mutant EFR inhibitor, in patients with treatment-resistant EGFR-driven NSCLC. Watch list After Hours Last Updated: 7:29 p.m. The company also initiated a phase I/II study for BLU-945, a triple-mutant EGFR inhibitor, to address patients with treatment-resistant EGFR-driven NSCLC. Overview Stock Screener Earnings Calendar Sectors Nasdaq BPMC U.S.: Nasdaq Blueprint Medicines Corp. In September 2020, the FDA approved Gavreto for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer (“NSCLC”).īlueprint Medicines initiated a phase II/III HARBOR study to evaluateBLU-263, a next generation KIT inhibitor, to treat non-advanced SM and other mast cell disorders. In December 2020, the FDA approved Gavreto (pralsetinib) for the treatment of patients with advanced/metastatic rearranged during transfection (“RET”)-mutant and RET fusion-positive thyroid cancer. ![]() In March 2021, the European Medicines Agency validated Blueprint Medicines’ Type II variation marketing authorization application seeking approval for Ayvakyt for treating advanced SM. We inform investors that Ayvakit was approved by the FDA in January 2020 for treating unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in adults. In June 2021, the FDA approved Blueprint Medicines’ supplemental new drug application (sNDA) seeking approval of Ayvakit for treating advanced systemic mastocytosis (SM), a rare and debilitating disease. Blueprint Medicines had cash, cash equivalents and investments worth $1.38 billion as of Jun 30, 2021, marginally lower than $1.43 billion as of Mar 31, 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |